Journal of the American Academy of Dermatology
Volume 63, Issue 2 , Pages 228-234 , August 2010

Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept

  • Robert Bissonnette, MD, FRCPC

      Affiliations

    • Innovaderm Research Inc, Montreal, Quebec, Canada
    • Corresponding Author InformationCorrespondence to: Robert Bissonnette, MD, Innovaderm Research Inc, 1851 Sherbrooke est, Bureau 502, Montreal, Quebec, H2K 4L5, Canada.
    • ,
  • Chantal Bolduc, MD, FRCPC

      Affiliations

    • Innovaderm Research Inc, Montreal, Quebec, Canada
    • ,
  • Yves Poulin, MD, FRCPC

      Affiliations

    • Centre de Recherche Dermatologique du Québec Métropolitain, Quebec, Canada
    • ,
  • Lyn Guenther, MD, FRCPC

      Affiliations

    • Guenther Dermatology Research Centre, London, Ontario, Canada
    • ,
  • Charles W. Lynde, MD, FRCPC

      Affiliations

    • Lynderm Research, Markham, Ontario, Canada
    • ,
  • Catherine Maari, MD, FRCPC

      Affiliations

    • Innovaderm Research Inc, Montreal, Quebec, Canada

,Accepted 25 August 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by Innovaderm Research Inc and an investigator grant from Abbott Laboratories.

 Disclosure: Dr Bissonnette has been a speaker, consultant, investigator, and/or advisory board member for Abbott, Amgen-Wyeth, Astellas-Pharma, Celgene, Centocor, EMD Serono, Galderma, Isotechnika, Leo Pharma, MedImmune, Ortho Biotech, Pfizer, and Schering-Plough Canada. He has received compensation in the form of grants and/or honoraria from these companies. Dr Bolduc has been a speaker, consultant, investigator, or advisory board member for Leo Pharma, Abbott, Amgen-Wyeth, Centocor, MedImmune, and Schering-Plough Canada. She has received compensation in the form of grants and/or honoraria from these companies. Dr Guenther has been a speaker, consultant, investigator, and advisory board member for Abbott, Amgen, Astellas-Pharma, Centocor, EMD Serono, Leo Pharma, Ortho Biotech, Novartis, Schering-Plough, and Wyeth. Dr Lynde has acted as a speaker and consultant for Astellas-Pharma, EMD Serono, Schering-Plough Canada, Abbott, Leo Pharma, and Amgen and receives compensation in the form of grants and honoraria. Dr Maari has been a speaker, consultant, investigator, and/or advisory board member for Abbott, Amgen-Wyeth, Astellas-Pharma, Centocor, Galderma, MedImmune, Ortho Biotech, and Schering-Plough Canada. She has received compensation in the form of grants and/or honoraria from these companies. Dr Poulin has been a speaker, consultant, investigator, and/or advisory board member for Abbott, Amgen-Wyeth, Astellas-Pharma, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor, EMD Serono, Galderma, Ortho Biotech, and Schering-Plough Canada. He has received compensation in the form of grants and/or honoraria from these companies.

 Reprints not available from the authors.

PII: S0190-9622(09)01150-5

doi: 10.1016/j.jaad.2009.08.040

Journal of the American Academy of Dermatology
Volume 63, Issue 2 , Pages 228-234 , August 2010

Article Tools

* Image Usage & Resolution